Maftivimab Explained

Type:	mab
Mab Type:	mab
Source:	u
Target:	Zaire ebolavirus glycoprotein
Pronounce:	maf tiv' i mab
Dailymedid:	Maftivimab
Pregnancy Us:	N
Class:	Monoclonal antibody
Atc Prefix:	None
Cas Number:	2135632-36-7
Unii:	KOP95331M4
Kegg:	D11450
C:	6368
H:	9886
N:	1706
O:	2008
S:	46

Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).^{[1] [2]}

External links

• Web site: Maftivimab . U.S. National Library of Medicine . Drug Information Portal .
• Web site: Statement on a nonproprietary name adopted by the USAN Council USAN (FG-103) Maftivimab .

Notes and References

1. FDA Approves First Treatment for Ebola Virus . U.S. Food and Drug Administration (FDA) . 14 October 2020 . 14 October 2020.
2. Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) . Regeneron Pharmaceuticals Inc. . 14 October 2020 . 14 October 2020.